Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Empowering Addison's Disease Players with DLI's Drug insights, clinical trial assessment, drug launch strategies and price reimbursement strategies | Disease Landscape Insights

This image opens in the lightbox

News provided by

Disease Landscape Insights

10 Oct, 2023, 06:01 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Oct. 10, 2023 /PRNewswire/ -- Addison's Disease is a rare adrenal gland disorder which is caused by adrenal gland damage. As per an epidemiology study by NIH, this ailment affects nearly 100 to 140 individuals of every million people. With proper treatment and medical supervision, most individuals with Addison's disease can lead normal and healthy lives.

Addison's disease is a chronic disorder that predominantly occurs when the adrenal glands fail to product sufficient amount of the cortisol and aldosterone hormones. This disease is also referred to as adrenal insufficiency It is worth noting that these hormones are responsible for the regulation of metabolism, immune response, and blood pressure. Cortisol deficiency can be fatal for many people since it leads to unregulated blood pressure.

Price and Market Access

Industry players are making extensive efforts to develop effective Addison's management solutions. They are engaged in continuous R&D activities with an aim to improve the quality of life of the patients affected with autoimmune adrenalitis. DiseaseLandscape Insights has been a support system to these players in their aim to efficiently deal with Addison's crisis. It has been helping them with drug development, treatment gaps identification, clinical trial feasibility analysis, new product development services, and regulatory consulting. DLI's healthcare consulting services also include price and market access strategies, product portfolio extension, overall clinical trial management, post launch services, along with commercial strategy analysis and product pipeline analysis. 

Primary Causes and Symptoms:

The major factors triggering the onset of this ailment are infections, such as tuberculosis, fungal infections, or HIV, long-term use of medications, such as certain antifungal drugs or steroids, and the occurrence of rare genetic disorders, like congenital adrenal hyperplasia, can cause adrenal insufficiency from birth.

Some of the primary symptoms associated with this ailment are adrenal fatigue, weight loss, hyperpigmentation, nausea, vomiting, salt cravings, increased thirst, low blood pressure, muscle and joint pain, low blood sugar, irritability, digestive issues, and weakness, among others.

Learn More About the FDA NDA & BLA Approval (NME) Drugs for Addison's Disease @

https://www.diseaselandscape.com/requestsample/postid/52 

Diagnosis and Treatment:

Addison's diagnosis involves a combination of medical evaluations and laboratory tests. The major ones include blood tests, medical history evaluation, ACTH stimulation test, and imaging tests like CT scan and MRI.

Coming to the treatment landscape, the adrenal hormone therapy also known as hormone replacement therapy works wonder in dealing with this ailment.  It involves the administration of a synthetic form of the missing hormone. Apart from that, stress management, lifestyle modifications, proper diet, and improved sleep cycle also provide the much-needed Addison's disease support. Patients with this disorder require regular follow-up with their healthcare provider to adjust medication dosages, monitor hormone levels, and assess overall health. Adoption of proper treatment at the right time helps the patients to lead a normal life.

Unlock the Benefits Today! Get Started Now and Elevate Your Experience @

https://www.diseaselandscape.com/checkout?report_id=52 

Summing Up:

Addison's Disease is a rare and chronic medical condition characterized by the underactivity of the adrenal glands, which are small glands located on top of each kidney. Common symptoms of Addison's Disease include fatigue, weakness, weight loss, low blood pressure, skin darkening, salt cravings, nausea, and more. It left untreated, Addison's Disease can be life-threatening, especially during times of stress or illness. DLI has been providing invaluable tools for healthcare professionals, researchers, and policymakers to make informed decisions regarding treatment options, ensuring that patients have access to the latest advancements in Addison's Disease management. By leveraging these insights, we can develop more effective therapies, streamline clinical trial processes, and optimize pricing and reimbursement strategies, ultimately reducing the burden of this chronic condition on both patients and healthcare systems. DLI together with the industry players are aimed at making meaningful strides in the fight against this devastating illness.

Browse Through More Autoimmune Diseases Research Reports.

Related Reports:

Advancing research into Parkinson's Disease Global Perspectives and Innovations in Care

Unlocking the Most Recent Advances in Alzheimer's Disease research: a glimmer of hope

Global Insights on Multiple System Atrophy (MSA) Disease: Rising Against the Odds

Understanding Crohn's Disease: Its Causes, Signs, and Treatment

Effective Psoriasis Disease Management Techniques: Unlocking Relief

Managing the Alzheimer's Landscape: How We Direct Market Participants to Unique Solutions

Healthcare is being revolutionized by AI-driven Personalized Medicine.

New Topical Drug Delivery Therapies Unlock the Future of Skin-Credible Care, Causing a Psoriasis Care Crisis!

By Lexicon Pharmaceuticals, whose , Inpefa endorsed by the FDA

The drug Xacduro from Innoviva Specialty Therapeutics will aid in the Treatment of Bacterial Pneumonia

Phase III Trials Show Effective Performance of Levodopa/Carbidopa's New Formulation ND0612: A Struggle Against Parkinson's Disease

Lotilaner as a Revolutionary Demodex Blepharitis Treatment

Elfabrio's Active Ingredient, Pegunigalsidase Alfa-IWXJ, May Aid in the Treatment of Fabry Disease

The Roadmap for a Successful Drug Launch's

Enabling Investor Excellence: Your Partner in Closing Gaps, Increasing Competitiveness, and Making a Global Impact

Managing the Immunotherapy World's Challenges

A case study involving the cooperation of a pharmaceutical business with CDMOs and SMOs

Case Study: Expansion of the Australian Product Portfolio

AI application in a healthcare organization: a case study

Case Study: Landscape Analysis of Ovarian Cancer Treatment

About Disease Landscape:  

Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.  

Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  

Contact Us:  

Disease Landscape Insights LLP 
6th Floor, Sr No.207, Office A H 6070 Phase 1 
Solitaire Business Hub, Viman Nagar 
Pune, Maharashtra, 411014 
Sales Contact: +44-2038074155 
Asia Office Contact: +917447409162
Email: ajay@diseaselandscape.com    
Email: vishal@diseaselandscape.com
Blog: https://www.diseaselandscape.com/blogs  
Case Study: https://www.diseaselandscape.com/casestudies   
Pharma consulting Services  
Follow Us: LinkedIn | Twitter | Facebook

Logo: https://mma.prnewswire.com/media/2217060/4328675/Disease_Landscape_Insights_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.